ABT
Abbott Laboratories
97.50$
+0.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 31.4% | 31.0% | 30.9% | 31.7% | 32.0% | 29.1% | 28.4% | 29.1% | 29.5% | 30.0% | 23.1% | 22.4% | |
| 9.3% | 9.4% | 8.7% | 9.6% | 10.2% | 9.4% | 8.0% | 8.3% | 8.9% | 9.8% | 6.2% | 4.7% | |
| 9.8% | 9.9% | 9.2% | 9.9% | 10.5% | 9.8% | 8.4% | 8.7% | 9.2% | 10.3% | 6.6% | 5.1% | |
| 9.0% | 9.0% | 9.1% | 9.4% | 9.5% | 8.5% | 9.0% | 9.5% | 9.7% | 9.1% | 7.4% | 7.9% | |
| 9.2% | 9.0% | 9.4% | 9.3% | 9.2% | 7.6% | 8.2% | 8.3% | 8.0% | 7.5% | 6.3% | 6.7% | |
| 13.3% | – | – | – | 14.3% | 13.1% | 13.4% | 13.6% | 13.7% | 13.6% | – | – | |
| 32.3% | 32.3% | 32.3% | 31.9% | 31.8% | 28.4% | 28.7% | 28.5% | 28.5% | 27.7% | 31.9% | 32.3% | |
| 12.9% | 12.0% | 11.4% | 10.7% | 9.9% | 8.2% | 7.7% | 7.0% | 6.6% | 6.4% | 16.2% | 15.8% | |
| 47.7% | 47.0% | 46.1% | 45.8% | 46.2% | 41.2% | 39.8% | 39.5% | 39.1% | 39.1% | 52.3% | 52.6% | |
| 18.1% | 18.9% | 19.3% | 18.8% | 20.0% | 17.4% | 16.0% | 16.0% | 17.3% | 19.0% | 16.6% | 16.3% | |
| 1.5% | 1.8% | 2.8% | 2.2% | 2.9% | 2.2% | 0.6% | 0.6% | 1.6% | 3.8% | 4.0% | 2.8% | |
| 5.5% | 5.9% | 5.8% | 5.6% | 5.4% | 5.2% | 5.2% | 5.1% | 4.9% | 4.9% | 4.2% | 4.4% | |
| 20.1% | 18.6% | 17.4% | 18.0% | 17.2% | 15.5% | 15.6% | 15.4% | 13.8% | 11.4% | 26.8% | – | |
| 52.0% | 52.7% | 53.6% | 53.8% | 53.5% | 58.5% | 59.9% | 60.2% | 60.5% | 60.1% | 47.1% | 46.8% | |
| 51.2% | 51.3% | 52.5% | 52.5% | 52.5% | 58.1% | 58.6% | 57.7% | 58.3% | 57.4% | 45.2% | 45.6% | |
| 2.4% | 2.4% | 2.4% | 2.4% | 2.4% | 2.1% | 2.1% | 2.1% | 2.1% | 2.0% | 1.6% | 1.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.